J&J Skids After Dow Giant Beat Earnings Views, But ”Prudent” Guidance Disappoints

Jeff Jonas, portfolio manager at Gabelli Funds, called out depression drug Spravato. Spravato sales rose 44% year over year to $297 million and narrowly topped forecasts.

IN THE NEWS

published January 22, 2025

800-Gabelli
info@gabelli.com

Other in the news

Biotech Stocks Trading Under Water Pose a Conundrum for Bargain-Hunters

May 8, 2025

Markets lurch on false Trump tariff pause report

April 7, 2025

This Week in Chancery Court: Paramount, Skydance Merger Records

April 6, 2025

Trade War Just Crashed Crude. Demand Might Be Next

April 6, 2025

2025 Gabelli Annual Meeting Replay Available Now

May 27, 2025

woman pointing at an AI screen with different images and she is selecting one with her finger

17th Annual Media & Sports Symposium

May 7, 2025

Trusted by clients since 1977

February 4, 2025

Invest with Gabelli today

1Contact

2About

First Name(Required)

Last Name(Required)

Email(Required)

Phone(Required)

Company

I am a:(Required)

Country(Required)

State(Required)

Comment

CAPTCHA

Investment Strategies

Separate Accounts

Open-End Funds

Closed-End Funds

ETFs

Money Markets

UCITS ( SICAV)

Private Wealth Management

All Investment Options

Research

Media

Events

Documents Archive

Forms & Applications

J&J Skids After Dow Giant Beat Earnings Views, But ”Prudent” Guidance Disappoints

IN THE NEWS

Other in the news

Biotech Stocks Trading Under Water Pose a Conundrum for Bargain-Hunters

Markets lurch on false Trump tariff pause report

This Week in Chancery Court: Paramount, Skydance Merger Records

Trade War Just Crashed Crude. Demand Might Be Next

2025 Gabelli Annual Meeting Replay Available Now

17th Annual Media & Sports Symposium

Trusted by clients since 1977

Invest with Gabelli today

GABELLI

Ways to Invest

Our Company

Knowledge

Information